Cell Signaling Technology

Product Pathways - DNA Damage

Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody #2981

14-3-3   general   motif   PBS   phospho serine   phospho-serine   phosphoserine   RXFXS   RXYXS   substrate  

No. Size Price
2981S 100 µl ( 10 western blots ) ¥4,050.00 现货查询 购买询价 防伪查询
2981 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype
W 1:1000 Human,Mouse,All Species Expected, Endogenous Rabbit
IP 1:50
E-P 1:1000

Species cross-reactivity is determined by western blot.

Applications Key: W=Western Blotting, IP=Immunoprecipitation, E-P=Peptide ELISA (DELFIA),

Specificity / Sensitivity

Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody detects endogenous levels of proteins containing the Arg-X-Tyr/Phe-X-pSer motif. This antibody does not cross-react with nonphosphorylated serine or phospho-threonine proteins with the same motif or other phospho-serine/threonine-containing proteins and peptides without this motif. (U.S. Patent No's.: 6,441,140; 6,982,318; 7,259,022; 7,344,714; U.S.S.N. 11,484,485; and all foreign equivalents.)

Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody识别包含Arg-X-Tyr/Phe-X-pSer基序的内源水平的蛋白质。该抗体不与非磷酸化丝氨酸残基、同样基序中磷酸化的苏氨酸残基、其它基序中的磷酸化丝氨酸/苏氨酸残基发生交叉反应。(美国专利号:6,441,140、6,982,318、7,259,022、7,344,714;U.S.S.N. 11,484,485;及所有国外相应专利)

Source / Purification

Polyclonal antibodies are produced by immunizing animals with Arg-X-Tyr/Phe-X-pSer-containing peptides . Antibodies are purified by protein A and peptide affinity chromatography.


Western Blotting

Western Blotting

Western blot analysis of extracts from A431 cells, untreated or calyculin A treated, using Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody.

对未处理或calyculin A处理的A431细胞抽提液使用Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody进行Western blot分析。


The 14-3-3 proteins are a highly conserved family of proteins involved in the regulation of cell survival, apoptosis, proliferation and checkpoint control (1-5). Binding of 14-3-3 is mediated through phospho-serine-containing proteins (6). Two different phospho-serine containing motifs are found using a degenerate phospho-serine-oriented peptide library technique, RSXS*XP and RXY/FXS*XP (6). Motif 2 (RXY/FXS*XP) is found in critical regulatory proteins including cdc25A, cdc25B, PKCgamma, IRS-1 and BCR (6). Although Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody binds 14-3-3 binding motif 2 with no requirement for proline in the +2 position, it provides a powerful tool for the discovery and characterization of potential 14-3-3 binding motif 2-containing proteins or other proteins with the RXY/FXS* motif.

14-3-3蛋白是参与调解细胞生存、凋亡、增殖和检查点调控的一组高度保守的蛋白家族(1-5)。14-3-3的结合由包含磷酸化丝氨酸的蛋白质介导(6)。两种包含磷酸化丝氨酸的基序在简并磷酸化导向肽库技术中发现,分别为RSXS*XP和RXY/FXS*XP(6)。基序2(RXY/FXS*XP)在很多重要的调节蛋白包括cdc25A、cdc25B、PKCγ、IRS-1和BCR中发现(6)。尽管Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody可以结合14-3-3结合基序2,并且不需要+2位上的脯氨酸,它仍然是发现和鉴定潜在包含14-3-3结合基序2蛋白或其它含RXY/FXS*基序蛋白的有力工具。

  1. Aitken, A. (1995) Trends Biochem Sci 20, 95-7.
  2. Zha, J. et al. (1996) Cell 87, 619-28.
  3. Piwnica-Worms, H. (1999) Nature 401, 535, 537.
  4. Tzivion, G. et al. (1998) Nature 394, 88-92.
  5. Xing, H. et al. (2000) EMBO J 19, 349-58.
  6. Yaffe, M.B. et al. (1997) Cell 91, 961-71.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!


Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commercial licensing terms please contact CST Pharma Services Department at ptmscan@cellsignal.com.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :